Neuropilin-1 Targeted Dual-Modality PET/NIRF Probe for the Noninvasive In Vivo Imaging of Triple-Negative Breast Cancer
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.5c00478 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Qingzhu Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, Chi…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Neuropilin-1, Positron-Emission Tomography. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Ministry of Science and Technology of the People's Republic of China, Wuxi Municipal Health Commission, Jiangsu Province Capability Improvement Project through Science, Technology and Education.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is a serious malignancy characterized by a lack of definitive biomarkers. Research has demonstrated that neuropilin-1 (NRP-1) is highly overexpressed in breast cancer, and its expression levels are strongly associated with the occurrence, development, and prognosis of tumors, thereby positioning NRP-1 as a promising target for the diagnosis and treatment of breast cancer, particularly for TNBC. Herein, NRP-1 was employed as a molecular marker to design and synthesize a PET/NIRF dual-modality molecular probe [18F]AmBF3-QS-1 for tumor localization and surgical navigation in TNBC. The nonradioactive NIRF probe AmBF3-QS-1 was synthesized through the click reaction (chemical purity >95%), and the radioactive probe [18F]AmBF3-QS-1 was synthesized via the one-step 18F-labeling method (radiochemical purity >95%, radiochemical yield >15%). The fluorescence imaging, flow cytometry, and cellular uptake studies in cancer cells with different NRP-1 expression levels were performed to verify the in vitro specificity of the probe. In vivo PET and NIRF imaging of MDA-MB-231 xenografts demonstrated excellent specificity of [18F]AmBF3-QS-1 for tumor uptake (8.41 ± 0.86%ID/mL, 9.67 ± 2.15 × 107 [p/sec/cm2/sr]/[μW/cm2]) with high-contrast ratios (5.91 ± 0.60, 2.80 ± 0.51). Additionally, ex vivo experiments showed that the probe AmBF3-QS-1 effectively guided tumor localization for precise resection and pathological examination. Collectively, the results demonstrate the potential of [18F]AmBF3-QS-1 as a promising dual-modality probe for noninvasive whole-body PET imaging to localize TNBC tumor as well as for NIRF imaging guidance to delineate tumor margins during surgical procedures.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, China.
ORCID-Profile: Qingzhu Liu, Jianguo Lin
Förderung
- Ministry of Science and Technology of the People's Republic of China
- Wuxi Municipal Health Commission
- Jiangsu Province Capability Improvement Project through Science, Technology and Education
- Jiangsu Provincial Department of Science and Technology
Zitieren
APA
Liu, Q., Qin, S., Cai, S., Qiu, L., & Lin, J. (2025). Neuropilin-1 Targeted Dual-Modality PET/NIRF Probe for the Noninvasive In Vivo Imaging of Triple-Negative Breast Cancer. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00478
Vancouver
Liu Q, Qin S, Cai S, Qiu L, Lin J. Neuropilin-1 Targeted Dual-Modality PET/NIRF Probe for the Noninvasive In Vivo Imaging of Triple-Negative Breast Cancer. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00478
BibTeX
@article{Liu2025,
author = {Liu, Qingzhu and Qin, Shuai and Cai, Shuyue and Qiu, Ling and Lin, Jianguo},
title = {Neuropilin-1 Targeted Dual-Modality PET/NIRF Probe for the Noninvasive In Vivo Imaging of Triple-Negative Breast Cancer},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.5c00478}
}
EUVIMED